Phathom Pharmaceuticals, Inc. Assets Liabilities Change (Total)

Assets Liabilities Change (Total) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Assets Liabilities Change (Total) growth rates and interactive chart.


Highlights and Quick Summary

  • Assets Liabilities Change (Total) for the quarter ending September 29, 2021 was $345 Thousand (a -89.55% decrease compared to previous quarter)
  • Year-over-year quarterly Assets Liabilities Change (Total) decreased by -98.47%
  • Annual Assets Liabilities Change (Total) for 2020 was $51.7 Million (a -643.13% decrease from previous year)
  • Annual Assets Liabilities Change (Total) for 2019 was $-9.52 Million (a -4528.84% decrease from previous year)
  • Twelve month Assets Liabilities Change (Total) ending September 29, 2021 was $6.57 Million (a -61.2% decrease compared to previous quarter)
  • Twelve month trailing Assets Liabilities Change (Total) decreased by -87.31% year-over-year
Trailing Assets Liabilities Change (Total) for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$6.57 Million $16.9 Million $24.1 Million $51.7 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Assets Liabilities Change (Total) of Phathom Pharmaceuticals, Inc.

Most recent Assets Liabilities Change (Total)of PHAT including historical data for past 10 years.

Interactive Chart of Assets Liabilities Change (Total) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Assets Liabilities Change (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.35 $3.3 $-19.59
2020 $22.5 $10.7 $10.51 $8.01 $51.72
2019 $-10.33 $0.54 $-0.17 $0.43 $-9.52
2018 $0.15 $0.06 $0.22

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.